ClinicalTrials.gg
RecruitingNCT07439939PORTHEMOSTUpdated Apr 21, 2026

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

An observational study in Liver Cirrhosis and Portal Hypertension, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, none of them phase 3. Liver Cirrhosis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
9th of 10
45 · median 226
Started
2026
with 1 other
Observational
10 of 16
3 open now
Registered
15th of 16
by date

Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 15th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

4 of the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Histological modificaitions fo the portal vein wall and haemostatic changes have been described in cirrhotic patients. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated. One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance. Inflammatory phenomena and NETosis may also be involved. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS). During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses. The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients.

Read the detailed description

Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Portal vein thrombosis associated with cirrhosis, which is most often non-occlusive (70%), is characterised by histological changes in the portal vein wall and the presence of an intraluminal thrombus.

In cirrhotic patients, histological changes are described at the portal level. In response to portal hypertension, the calibre of the portal vein, where circulation is at low pressure and high compliance, increases. In response to this mechanical stress, intimal hypertrophy and fibroblast proliferation are observed. In cases of portal vein thrombosis, these changes are more pronounced. Changes in haemostatic balance are also observed in these patients. Thrombocytopenia and decreased synthesis of coagulation factors on the one hand, and decreased coagulation cascade and fibrinolytic regulatory factors on the other, contribute to creating a new fragile haemostatic balance. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated.

One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor (VWF) and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance.

This hypothesis is supported by several studies showing that cirrhotic patients have higher portal than systemic levels of VWF, factor VIII and lipopolysaccharides. Inflammatory phenomena and NETosis may also be involved.

The vascular endothelial surface is covered by the glycocalyx, with antithrombotic and anti-inflammatory effects that regulates vascular permeability. The endothelial glycocalyx has three major components: proteoglycans binding to the endothelial membrane, sulphated glycosaminoglycans bound laterally to proteoglycans, and plasma proteins. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS).

During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses.

The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients. To our knowledge, studies conducted to date have not investigated haemostasis under flow conditions, which are more physiological than static investigations.

03

Conditions studied

  • Liver Cirrhosis
  • Portal Hypertension

Keywords

  • liver cirrhosis
  • portal hypertension
  • Transjugular Intrahepatic Portosystemic Shunt
  • Primary Hemostasis
  • Blood Coagulation
  • Fibrinolysis
  • Thromboinflammation
  • von Willebrand Factor
  • Endothelial Dysfunction
  • Portal Circulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cirrhosis, regardless of the underlying cause, undergoing TIPS placement, regardless of the indication.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged ≥18 years) covered by a social security scheme or entitled beneficiaries
  • Patients followed for a cirrhotic condition at Paul Brousse Hospital and undergoing placement of a TIPS (transjugular intrahepatic portosystemic shunt)

Exclusion criteria

Exclusion Criteria:

  • Patient unwilling to participate in the study
  • Patient with a to TIPS placement
  • Patient with a known hemostatic disorder unrelated to cirrhosis
  • Patient receiving treatment that interferes with hemostasis and has not been discontinued for the procedure
  • Patient receiving systemic therapy
  • Patient under legal protection
  • Patient not covered by a social security scheme
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of primary hemostasis assessed by T-TAS®01 at 10 minutes

    The primary outcome measure is the area under the curve (AUC) obtained at 10 minutes of perfusion during the assessment of primary hemostasis using the T-TAS®01 microfluidic system. Measurements are performed with PL chips coated with collagen. Under these conditions, thrombus formation is dependent on von Willebrand factor, allowing evaluation of primary hemostasis at the systemic and portal levels in patients with cirrhosis.

    Time frame: At 10 minutes of perfusion during the T-TAS®01 primary hemostasis assessment procedure

Secondary outcomes

  1. Time to reach 10 kPa above baseline pressure in the T-TAS®01 system

    Time required to reach a pressure of 10 kPa above baseline during perfusion in the T-TAS®01 microfluidic system, measured on systemic and portal blood samples

    Time frame: At the time of TIPS placement

  2. Time to reach 60 kPa above baseline pressure in the T-TAS®01 system

    Time required to reach a pressure of 60 kPa above baseline during perfusion in the T-TAS®01 microfluidic system, measured on systemic and portal blood samples

    Time frame: At the time of TIPS placement

  3. Conventional coagulation parameters at systemic and portal levels

    Prothrombin time, activated partial thromboplastin time ratio, factor V, fibrinogen (Clauss method), antithrombin, factor VIII, von Willebrand factor antigen and activity, and ADAMTS-13 activity measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  4. Fibrinolysis parameters at systemic and portal levels

    Tissue plasminogen activator antigen and activity, plasminogen activator inhibitor-1 antigen and activity, D-dimers, protease nexin-1, and global fibrinolytic capacity measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  5. Complete blood count parameters at systemic and portal levels

    Complete blood count parameters including hemoglobin, hematocrit, leukocytes, and platelet count measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  6. ROTEM® coagulation parameters at systemic and portal levels

    ROTEM® EXTEM and INTEM parameters including clotting time, clot formation time, amplitude at 5 minutes, and maximum clot firmness measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  7. Thrombin generation parameters at systemic and portal levels

    Thrombin generation test parameters including lag time, time to peak, peak thrombin, endogenous thrombin potential, velocity index, and end of test time, assessed with and without thrombomodulin in systemic and portal samples

    Time frame: At the time of TIPS placemen

  8. Inflammatory biomarkers at systemic and portal levels

    Albumin, C-reactive protein, interleukin-6, and lipopolysaccharides measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  9. Endothelial and glycocalyx biomarkers at systemic and portal levels

    Angiopoietin-1, angiopoietin-2, glycosaminoglycans, heparan sulfate, syndecan, soluble thrombomodulin, and soluble P-selectin measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  10. Markers of thrombo-inflammation and NETosis at systemic and portal levels

    Cell-free DNA, citrullinated histone-3, DNA-histone-3 complexes, and DNase activity measured in systemic and portal blood samples

    Time frame: At the time of TIPS placement

  11. Child-Pugh score

    Assessment of liver disease severity using the Child-Pugh score (range 5-15, higher scores indicate more severe liver disease), measured prior to TIPS placement

    Time frame: Prior to TIPS placement

  12. MELD score

    Assessment of liver disease severity using the Model for End-Stage Liver Disease (MELD) score, measured prior to TIPS placement

    Time frame: Prior to TIPS placement

  13. Portal-systemic pressure gradient

    Measurement of the porto-systemic pressure gradient prior to TIPS placement

    Time frame: Prior to TIPS placement

  14. Occurrence of TIPS thrombosis at Day 90

    Occurrence of partial or complete thrombosis of the TIPS or a portal vein branch within 90 days after TIPS placement

    Time frame: Up to 90 days after TIPS placement

  15. Need for TIPS revision or recalibration at Day 90

    Need for TIPS revision or recalibration within 90 days after TIPS placement

    Time frame: Up to 90 days after TIPS placement

  16. Major clinical events at Day 90

    Occurrence of liver transplantation, gastrointestinal bleeding, or TIPS infection within 90 days after TIPS placement

    Time frame: Up to 90 days after TIPS placement

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 15 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 27, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Jun 9, 2027
CompletionEst.
Jun 9, 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07439939
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 9, 2026
Primary completion
Jun 9, 2027 (estimated)
Completion
Jun 9, 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Stéphanie ROULLET stephanie.roullet@aphp.fr, PhD
Contact
stephanie.roullet@aphp.fr
145596949 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion